MOR has been the topic of a number of other reports. Goldman Sachs Group set a €72.00 ($85.71) price target on shares of MorphoSys and gave the company a neutral rating in a report on Wednesday, November 8th. Berenberg Bank set a €85.00 ($101.19) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, November 1st. Deutsche Bank set a €90.00 ($107.14) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Wednesday, November 8th. Independent Research set a €93.00 ($110.71) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Friday, December 1st. Finally, Commerzbank set a €76.00 ($90.48) target price on shares of MorphoSys and gave the stock a buy rating in a research note on Thursday, September 21st. One research analyst has rated the stock with a sell rating, two have given a hold rating and six have issued a buy rating to the company. The company has an average rating of Buy and a consensus price target of €81.56 ($97.09).
MorphoSys (ETR:MOR) traded down €3.95 ($4.70) during trading hours on Monday, hitting €83.10 ($98.93). 270,503 shares of the stock were exchanged, compared to its average volume of 124,968. MorphoSys has a twelve month low of €47.10 ($56.07) and a twelve month high of €87.05 ($103.63). The company has a market cap of $2,460.00 and a PE ratio of -28.17.
ILLEGAL ACTIVITY WARNING: This piece of content was first published by Markets Daily and is the sole property of of Markets Daily. If you are accessing this piece of content on another website, it was illegally copied and reposted in violation of U.S. & international trademark and copyright legislation. The correct version of this piece of content can be accessed at https://www.themarketsdaily.com/2018/01/19/jpmorgan-chase-co-reaffirms-buy-rating-for-morphosys-mor.html.
MorphoSys AG, together with its subsidiaries, engages in the research, development, and optimization of therapeutic antibody drug candidates in partnerships with pharmaceutical and biotechnology companies. The company, together with its pharmaceutical partners, develops a therapeutic pipeline of approximately 100 human antibody drug candidates for the treatment of cancer, rheumatoid arthritis, Alzheimer's disease, infectious diseases, cardiovascular dysfunction, and inflammation.
Receive News & Ratings for MorphoSys Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for MorphoSys and related companies with MarketBeat.com's FREE daily email newsletter.